{"preliminary_commentary":{"by_channel":{"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06382116\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PANKU-Lung01","nct_id":"NCT06382116","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=panku-lung01-nct06382116. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.","label":"BL-B01D1","type":"EXPERIMENTAL"},{"description":"Participants receive Pemetrexed +Cisplatin or Carboplatin in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.","label":"Pemetrexed+Cisplatin or Carboplatin","type":"EXPERIMENTAL"}],"collaborators":["Baili-Bio (Chengdu) Pharmaceutical Co., Ltd."],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":432,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"BL-B01D1","otherNames":["iza-bren","izalontamab brengitecan","BMS-986507"],"type":"DRUG"},{"name":"Pemetrexed+Cisplatin or Carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-23","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","official_title":"A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"Up to approximately 24 months"}],"references":[],"start_date":{"date":"2024-05-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)","url":"https://clinicaltrials.gov/study/NCT06382116"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/panku-lung01-nct06382116"}